Monoclonal antibody for colorectal cancer
A monoclonal antibody targeting epidermal growth factor receptors (EGFR) has been licensed for the treatment of metastatic colorectal cancer.
Cetuximab (Erbitux), manufactured by Merck, is licensed for use in combination
with irinotecan (Campto) in patients with metastatic colorectal cancer
expressing the growth factor, after previous therapy including irinotecan
has failed.
The expression of the EGFR protein is associated with more aggressive
disease and a poor prognosis. By blocking this protein,
cetuximab inhibits its function, preventing
tumour spread and possibly also impairing formation of the tumour blood
supply.
Cetuximab is administered weekly by intravenous infusion at an initial
dose of 400mg per m2 body surface area. Subsequent weekly doses are 250mg
per m2 following premedication with an antihistamine. Irinotecan should
be administered at least an hour after the cetuximab infusion and the
dose should normally be the same as that given in the prior regimen.
Notice-board p49
Clarification
Premedication with an antihistamine is mandatory before the first infusion of cetuximab, and is then recommended before all subsequent infusions. |
|
The
Pharmaceutical Journal
Acrobat
Reader